Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chondroitin sulfate 0.18% refers to an ophthalmic solution containing chondroitin sulfate at this specific concentration. Chondroitin sulfate is a sulfated glycosaminoglycan, a key structural component of the extracellular matrix in connective tissues, including those of the eye. In ophthalmic formulations, it functions as a lubricant and moisturizer, helping to stabilize the tear film and maintain the ocular microenvironment. It also exhibits anti-inflammatory properties by reducing pro-inflammatory mediators and inhibiting enzymes like metalloproteinases, and promotes the regeneration and repair of corneal cells. Additionally, it provides antioxidant protection by neutralizing free radicals and strengthens the eye's barrier function. This specific concentration is notably found as an ingredient in combination ophthalmic solutions, often with sodium hyaluronate, used for conditions such as dry eye syndrome and as a viscoelastic agent during eye surgeries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chondroitin sulfate 0.18%.